Shenyang Xingqi PharmaceuticalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Shenyang Xingqi PharmaceuticalLtd wird ein jährliches Gewinn- und Umsatzwachstum von 32.8% bzw. 22.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 32.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22.1% betragen.

Wichtige Informationen

32.8%

Wachstumsrate der Gewinne

32.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	18.8%
Wachstumsrate der Einnahmen	22.6%
Zukünftige Eigenkapitalrendite	22.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	23 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/E Is Still On The Mark Following 49% Share Price Bounce

Oct 23

Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing

Sep 08

With EPS Growth And More, Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Makes An Interesting Case

Aug 19

What You Can Learn From Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/S After Its 27% Share Price Crash

Jul 24

Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?

Jun 28

Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Increasing Its Dividend To CN¥3.00

May 21

After Leaping 31% Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares Are Not Flying Under The Radar

May 10

We Ran A Stock Scan For Earnings Growth And Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Passed With Ease

May 07

Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Looks Just Right With A 26% Price Jump

Mar 15

Gewinn- und Umsatzwachstumsprognosen

SZSE:300573 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,082	768	N/A	1,474	1
12/31/2025	2,680	669	N/A	1,171	1
12/31/2024	2,117	449	N/A	867	1
9/30/2024	1,802	348	270	447	N/A
6/30/2024	1,674	322	211	400	N/A
3/31/2024	1,531	255	153	343	N/A
12/31/2023	1,468	240	56	318	N/A
9/30/2023	1,350	191	8	254	N/A
6/30/2023	1,335	179	27	256	N/A
3/31/2023	1,234	157	-103	241	N/A
1/1/2023	1,250	212	-13	286	N/A
9/30/2022	1,262	241	90	378	N/A
6/30/2022	1,166	235	80	362	N/A
3/31/2022	1,123	236	234	363	N/A
1/1/2022	1,028	195	212	307	N/A
9/30/2021	990	190	156	243	N/A
6/30/2021	914	153	92	186	N/A
3/31/2021	813	132	68	167	N/A
12/31/2020	689	88	14	122	N/A
9/30/2020	602	61	0	81	N/A
6/30/2020	528	45	-28	51	N/A
3/31/2020	514	24	-21	64	N/A
12/31/2019	542	36	4	74	N/A
9/30/2019	504	29	-9	62	N/A
6/30/2019	480	21	-13	45	N/A
3/31/2019	453	17	4	48	N/A
12/31/2018	431	14	-1	44	N/A
9/30/2018	416	11	8	58	N/A
6/30/2018	379	9	N/A	63	N/A
3/31/2018	362	28	N/A	28	N/A
12/31/2017	360	39	N/A	33	N/A
9/30/2017	361	51	N/A	11	N/A
6/30/2017	356	51	N/A	10	N/A
3/31/2017	347	55	N/A	32	N/A
12/31/2016	339	54	N/A	28	N/A
12/31/2015	287	22	N/A	21	N/A
12/31/2014	255	31	N/A	13	N/A
12/31/2013	219	46	N/A	8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 300573Das prognostizierte Gewinnwachstum (32.8% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 300573Die Erträge des Unternehmens (32.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (26.2% pro Jahr).

Hohe Wachstumserträge: 300573Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 300573Die Einnahmen des Unternehmens (22.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 300573Die Einnahmen des Unternehmens (22.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 300573Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22.1%)

Shenyang Xingqi PharmaceuticalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.70 (vs CN¥0.54 in 3Q 2023)

Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/E Is Still On The Mark Following 49% Share Price Bounce

Investor sentiment deteriorates as stock falls 28%

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing

Investor sentiment deteriorates as stock falls 19%

Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024

Second quarter 2024 earnings released: EPS: CN¥0.77 (vs CN¥0.39 in 2Q 2023)

With EPS Growth And More, Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Makes An Interesting Case

High number of new directors

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

What You Can Learn From Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/S After Its 27% Share Price Crash

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?

Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Increasing Its Dividend To CN¥3.00

Dividend of CN¥3.00 announced

Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024

After Leaping 31% Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares Are Not Flying Under The Radar

We Ran A Stock Scan For Earnings Growth And Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Passed With Ease

First quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in 1Q 2023)

Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Looks Just Right With A 26% Price Jump

Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.66 in 3Q 2022)

New major risk - Share price stability

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023

Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023

High number of new directors

Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: CN¥2.41 (vs CN¥2.39 in FY 2021)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.93 (vs CN¥0.90 in 3Q 2021)

Shenyang Xingqi Pharmaceutical Co.,Ltd Announces Interim Dividend on A Shares for the Year 2021, Payable on September 23, 2022

Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Interim Cash Dividend for 2022

Shenyang Xingqi Pharmaceutical Announces Profit Distribution Proposal for the First Half of 2022

Second quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in 2Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shenyang Xingqi Pharmaceutical Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented on A Shares, Payable on 20 May 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.40 in 1Q 2021)

Shenyang Xingqi Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings released: EPS: CN¥2.39 (vs CN¥1.09 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.47 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Shenyang Xingqi Pharmaceutical Co., Ltd. Announces Final Cash Dividend for the Year 2020, Payable on 21 May 2021

Full year 2020 earnings released: EPS CN¥1.09 (vs CN¥0.45 in FY 2019)

Shenyang Xingqi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥93.15

Shenyang Xingqi Pharmaceutical Co., Ltd. Approves Directorate Elections

New 90-day low: CN¥107

New 90-day low: CN¥124

Third quarter earnings released

New 90-day low: CN¥129

New 90-day low - CN¥136

Shenyang Xingqi Pharmaceutical Co.,Ltd announced that it expects to receive CNY 800 million in funding